VK2735

InvestigationalMetabolic ResearchWeight & metabolic
5.3

Neutral, BioHarmony verdict

BioHarmony score 5.3 out of 10

VK2735 is an investigational dual GLP-1 and GIP receptor agonist from Viking Therapeutics that produced about 14.7 percent weight loss at 13 weeks in its peer-reviewed VENTURE Phase 2 injectable trial, per Bays 2026. Every dataset is 13 weeks or shorter and it is not approved.

Read full report

What is VK2735?

VK2735 is an investigational weight-loss and metabolic drug from Viking Therapeutics that activates two gut hormone receptors at once, the GLP-1 receptor and the GIP receptor. That dual-incretin design is the exact same mechanism behind tirzepatide, the approved drug sold as Mounjaro and Zepbound. The whole reason I'm scoring VK2735 is that it sits at the earliest stage of the next-generation incretin batch, and its early numbers are strong enough to take seriously. In its one peer-reviewed trial, the injectable form drove about 14.7 percent weight loss in just 13 weeks. That is genuinely competitive with the best in class, and I dig into that study in the Upside Rationale below.

From the BioHarmony report, reviewed Sep 8, 2026.

Saved on this device only.

How it is thought to work

Activates GLP-1 and GIP receptors together for appetite suppression, slowed gastric emptying, and glucose-dependent insulin release

Safety watch-outs

  • Severe or persistent abdominal pain, especially radiating to the back (possible pancreatitis): stop and seek care.
  • A neck lump, hoarseness, or trouble swallowing (the class carries a thyroid C-cell tumor warning): stop and consult a clinician.
  • Severe, ongoing vomiting or dehydration: stop and rehydrate, and seek care if it does not settle.
  • Any unverified or research-chemical-grade source: do not inject or ingest, since purity and contamination are unknown.

Full risk profile in the BioHarmony report.

Dosing as published

Source-reported figures only. This page does not calculate a personal dose.

No approved-label or study protocol is recorded for VK2735 yet.

More reported protocols

Members

Members can compare additional reported doses, schedules, and preparation notes.

Trust & sourcing

  1. Last revieweddone
  2. Next reviewupcoming
US approvalInvestigational
CompoundingNo FDA-approved product; compounding eligibility is not established

Viking Therapeutics reports that subcutaneous VK2735 is in phase 3 development for obesity, with oral VK2735 also advancing.

Primary sources

The Ultimate Peptides Guide

Spot stronger candidates, weak evidence, and seller red flags before you buy.

Free. Includes evidence and regulatory updates. Unsubscribe anytime.